Free Trial

GER Health Min Denies Handelsblatt Rpt, Fallout Still Being Felt

POLITICAL RISK

Alex Wickham at Politico tweets: "The German Health Ministry has DENIED the Handelsblatt report claiming the AstraZeneca had only 8% efficacy for over-65s. They say there has been confusion and 8% actually refers to the number of people in the study between 56 and 69 years old."

  • The denial comes after a bombshell article from German outlet Handelsblatt last night, which claimed that according to a German Health Ministry study, the AstraZeneca/Oxford University COVID-19 vaccine was only 8% effective for the over-65's.
  • This sparked immediate and angry rebukes from AstraZeneca as well as the UK gov't. Politico this morning quotes a 'Whitehall insider' accusing the German press of 'Russian-style disinformation'.
  • AstraZeneca finds itself in the firing line of EU leaders at present, with an issue at its Belgian production facility set to see a 60% shortfall on its initial order of vaccines to the EU. There is anger both at the shortfall, with the EU asking why vaccines were not mass produced before its approval by the EMA, and at the fact that supply to the UK, which is racing ahead in its vaccination rollout, is not disrupted.
  • The EU has raised the prospect of halting exports of the Pfizer/BioNTech vaccine to the UK from its production sites in Belgium if the bloc's supply is limited by other firms (i.e. AstraZeneca). The bloc enacted similar measures early in the pandemic in limiting the export of PPE outside the EU when it was required by member states.
  • The Handelsblatt story risks a major blow to UK-German relations if the report is believed to have damaged the AZ vaccine's reputation or caused concern among the UK population towards the vaccine.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.